News

Glucagon-like peptide 1 receptor agonists may offer neuroprotective and survival benefits beyond blood sugar control.
The study included 12 patients who suffer from a subset of Type 1 diabetes known as hypoglycemic unawareness, characterized ...
GLP-1RA users had a 37% lower risk of developing dementia compared to those on other antidiabetic drugs. Stroke risk reduced ...
A population-based cohort study emulating a target trial estimated the effect of glucagon-like peptide-1 receptor agonists ...
Type 1 diabetes is more prevalent in Finland than anywhere else in the world, affecting approximately 50,000 people.
In older patients with cancer and type 2 diabetes, glucagon-like peptide-1 receptor agonist (GLP-1RA) use was associated with ...
Individuals with type 2 diabetes who receive treatment with GLP-1 RAs do not have an increased risk for acute pancreatitis.
New stem cell therapy offers hope for type 1 diabetes, freeing patients from insulin. Learn why diverse clinical trial ...
A ‘groundbreaking’ drug to slow down the development of type 1 diabetes is being tried by a handful of patients in the UK.
A mother of two has become the first adult in the UK to try a “groundbreaking” drug which can delay the need for insulin in ...
MIT engineers developed an implantable reservoir that can remain under the skin and be triggered to release glucagon when ...
The new Barbie wears continuous glucose monitor (CGM), a device that tracks blood sugar levels, on her arm — while holding a ...